Viking Therapeutics, Inc. stock jumps 3.86% but bearish trend still holds

VKTX — daily chart with candlesticks, EMA20/EMA50 and volume.

Key takeaways

• Viking Therapeutics, Inc. stock closed at $30.11 on Monday, gaining 3.86% from the prior close of $28.99.
• The daily trend remains bearish, with price trading below the EMA20 ($31.82), EMA50 ($33.03), and EMA200 ($33.18).
• Daily RSI14 at 38.51 signals ongoing selling pressure, though not yet in oversold territory.
• The 1H MACD has turned positive, confirming a short-term momentum shift within the broader downtrend.
• The 15m RSI14 at 72.59 is overbought, suggesting the rally may pause before further upside.

Viking Therapeutics, Inc. stock closed Monday at $30.11, up 3.86%, as a sharp rally tested the prevailing bearish daily trend. The tension between strong short-term momentum and a weaker underlying structure now defines the technical outlook for VKTX.

Daily Trend: Bearish Structure Holds for Viking Therapeutics Stock

Viking Therapeutics stock remains in a bearish daily trend. Price at $30.11 sits below the EMA20 ($31.82), EMA50 ($33.03), and EMA200 ($33.18). This forms a textbook downtrend signature that sellers have maintained for weeks.

On the momentum front, RSI14 on the daily reads 38.51, below the neutral 50 line but not yet oversold. This leaves room for further downside, though selling pressure has eased from more extreme readings. MACD confirms the negative structure: the line sits at -1.19, below the signal at -0.83, with a histogram of -0.35. Notably, the histogram is less stretched than it could be, hinting that downside momentum may be decelerating.

Bollinger Bands provide useful context. The mid-band sits at 32.33, the upper band at 35.92, and the lower band at 28.73. Monday’s low of 28.41 pushed price near that lower band before the rebound — typically where short-term buyers step in. ATR14 at 1.49 confirms elevated volatility. Meanwhile, on the pivot framework, price closed above the daily pivot of 29.74. It is now working toward R1 at 31.07, with S1 at 28.78 as the nearest downside cushion.

1H View: Short-Term Momentum Turns Positive

The 1H chart shows momentum turning positive for Viking Therapeutics stock. Price at $30.12 trades above the EMA20 ($29.36) and near the EMA50 ($30.21), though it remains below the EMA200 at $32.41.

RSI14 on the 1H reads 56.6, a neutral-to-firm reading supporting an active bounce rather than a fading one. MACD on this timeframe has turned positive. The histogram flipped to +0.18, while the line (-0.24) closes in on the signal (-0.42). This MACD crossover signals early-stage bullish momentum within a shorter window.

However, the Bollinger setup shows price pressing against the upper band at 30.18, with the mid-band at 29.20. This stretched hourly position suggests the rally may be hitting short-term resistance rather than breaking cleanly higher. The 1H pivot point at 30.11 matches the closing price, putting VKTX at a decision level. R1 at 30.57 is the next test, with S1 at 29.66 as immediate support.

15m Execution Context: Overbought Conditions Flash Caution

The 15-minute chart shows overheated momentum. RSI14 sits at 72.59, firmly in overbought territory. Meanwhile, price at $30.12 trades above the upper Bollinger band of $30.01.

Meanwhile, the MACD histogram is positive at 0.18, consistent with the broader 1H bullish tilt. However, an RSI reading this high on a short timeframe typically signals a pause or pullback is more likely than immediate continuation. Traders using this timeframe should treat the 15m pivot levels as tactical markers rather than trend signals. These levels stand at pp 30.22, r1 30.46, and s1 29.89.

Reconciling Conflicting Signals Across Timeframes

Viking Therapeutics, Inc. stock currently shows a classic bounce-within-downtrend pattern. The daily bias remains bearish: price is below all three key EMAs, MACD is negative, and RSI is under 50. At the same time, the 1H timeframe confirms a genuine short-term bounce, with momentum turning positive and price reclaiming its EMA20 and EMA50. This is not yet confirmation of a trend reversal.

At the same time, the 15m overbought reading reinforces that the current push may need a breather before any further advance. Traders should view this as a market testing resistance within a broader downtrend, not establishing a new bullish regime.

News Catalysts Behind the Rally

Notably, the move coincides with sector-wide catalysts. Novo Nordisk signaled bigger M&A ambitions, targeting over $23 billion in risk-adjusted pipeline sales by 2035. This lifted VKTX alongside peers GPCR and ALT. Meanwhile, upcoming maintenance data for Viking’s VK2735, as it advances into late-stage trials, also drew attention. Both catalysts explain the conviction behind Monday’s rally, even as the daily chart structure remains unchanged.

Bullish Scenario: What Would Confirm a Reversal

For the bullish case to gain traction, Viking Therapeutics stock must clear the daily R1 at $31.07. It must then work through the EMA20 at $31.82. A close above the EMA50/EMA200 cluster near $33.00–$33.18 would signal the daily downtrend is losing control.

Confirmation would ideally come with the daily MACD histogram continuing to narrow its negative gap, alongside sustained volume on breakout attempts. Continued positive newsflow around VK2735 trial progress or renewed M&A speculation in the GLP-1 space could support that continuation.

Bearish Scenario: What Would Invalidate the Rally

On the other hand, a rejection near the 1H upper Bollinger band and R1 resistance would invalidate the bullish attempt quickly. A drop back below the 1H EMA20 at $29.36 and the daily pivot at $29.74 would open the door lower. This would target a retest of S1 at $28.78.

That level lines up closely with the daily lower Bollinger band at $28.73. If the 15m RSI unwinds sharply from its overbought level, the retracement could happen fast. In that case, the daily bearish regime reasserts itself, and Monday’s rally gets categorized as a relief bounce rather than a turning point.

Closing Take: Viking Therapeutics Stock at an Inflection Point

Overall, Viking Therapeutics, Inc. stock sits at a genuine inflection point between timeframes. The daily chart still favors sellers, but the 1H momentum shift and news-driven catalyst behind Monday’s rally cannot be dismissed.

Meanwhile, volatility, as measured by ATR, remains elevated at 1.49. The overbought 15m reading suggests near-term chop before the next directional move clarifies. Given mixed signals across timeframes, this looks like a market in transition rather than one with a settled trend. Positioning should reflect that uncertainty rather than conviction in either direction.

FAQ

Is Viking Therapeutics stock in a bull or bear trend?

Viking Therapeutics stock remains in a bearish daily trend. Price at $30.11 trades below the EMA20 ($31.82), EMA50 ($33.03), and EMA200 ($33.18). RSI14 at 38.51 and a negative MACD confirm sellers still control the broader tape.

What key levels should traders watch for VKTX?

Key resistance sits at R1 ($31.07), the EMA20 ($31.82), and the EMA50/EMA200 cluster near $33.00–$33.18. Key support stands at S1 ($28.78) and the daily lower Bollinger band ($28.73). The daily pivot at $29.74 and the 1H EMA20 at $29.36 also serve as near-term reference points.

What news is driving Viking Therapeutics stock?

Two catalysts lifted VKTX on Monday. First, Novo Nordisk signaled larger M&A ambitions, targeting over $23 billion in risk-adjusted pipeline sales by 2035. Second, upcoming maintenance data for Viking’s VK2735, as it moves into late-stage trials, drew renewed attention.

Is the VKTX rally sustainable?

The sustainability question remains open. The 1H chart shows genuine bullish momentum, but the daily trend is still bearish and the 15m RSI at 72.59 signals overbought conditions. Until VKTX clears the EMA20 at $31.82, the rally remains a bounce within a downtrend rather than a confirmed reversal.

Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument or cryptocurrency. The analysis provided is not indicative of future results. Investing in crypto assets and financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.

Article produced with the assistance of artificial intelligence and reviewed by the editorial team.